Cogent Biosciences, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Cogent Biosciences, Inc. (COGT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$70.63 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-12
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$70.63M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$58.95M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$58.35M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$54.37M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$192.41M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$140.24M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$72.27M.
- Cogent Biosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$179.21M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$70.63M 10-Q · filed 2024-11-12 | -$129.58M derived: sum of 2 quarters · filed 2024-11-12 | -$187.93M 10-Q · filed 2024-11-12 | -$242.30M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | -$58.95M 10-Q · filed 2024-08-06 | -$117.30M 10-Q · filed 2024-08-06 | -$171.66M derived: sum of 3 quarters · filed 2024-08-06 | -$227.04M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | -$58.35M 10-Q · filed 2024-05-07 | -$112.71M derived: sum of 2 quarters · filed 2024-05-07 | -$168.09M derived: sum of 3 quarters · filed 2024-11-12 | -$212.17M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | -$54.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$109.75M derived: sum of 2 quarters · filed 2024-11-12 | -$153.82M derived: sum of 3 quarters · filed 2024-11-12 | -$192.41M 10-K · filed 2024-02-26 |
| 2023-09-30 | -$55.38M 10-Q · filed 2024-11-12 | -$99.46M derived: sum of 2 quarters · filed 2024-11-12 | -$138.04M 10-Q · filed 2024-11-12 | -$177.66M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$44.08M 10-Q · filed 2024-08-06 | -$82.66M 10-Q · filed 2024-08-06 | -$122.28M derived: sum of 3 quarters · filed 2024-08-06 | -$157.34M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$38.59M 10-Q · filed 2024-05-07 | -$78.20M derived: sum of 2 quarters · filed 2024-05-07 | -$113.27M derived: sum of 3 quarters · filed 2024-05-07 | -$148.19M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$39.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$74.68M derived: sum of 2 quarters · filed 2024-02-26 | -$109.61M derived: sum of 3 quarters · filed 2024-02-26 | -$140.24M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$35.06M 10-Q · filed 2023-11-07 | -$69.99M derived: sum of 2 quarters · filed 2023-11-07 | -$100.62M 10-Q · filed 2023-11-07 | -$125.53M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$34.93M 10-Q · filed 2023-08-08 | -$65.56M 10-Q · filed 2023-08-08 | -$90.47M derived: sum of 3 quarters · filed 2024-02-26 | -$109.56M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$30.63M 10-Q · filed 2023-05-09 | -$55.55M derived: sum of 2 quarters · filed 2024-02-26 | -$74.63M derived: sum of 3 quarters · filed 2024-02-26 | -$91.18M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$24.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$44.00M derived: sum of 2 quarters · filed 2024-02-26 | -$60.55M derived: sum of 3 quarters · filed 2024-02-26 | -$72.27M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$19.08M 10-Q · filed 2022-11-14 | -$35.63M derived: sum of 2 quarters · filed 2022-11-14 | -$47.36M 10-Q · filed 2022-11-14 | -$163.10M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$16.55M 10-Q · filed 2022-08-09 | -$28.28M 10-Q · filed 2022-08-09 | -$144.01M derived: sum of 3 quarters · filed 2022-08-09 | -$194.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$11.73M 10-Q · filed 2022-05-10 | -$127.47M derived: sum of 2 quarters · filed 2022-05-10 | -$177.45M derived: sum of 3 quarters · filed 2022-05-10 | -$184.84M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$115.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$165.72M derived: sum of 2 quarters · filed 2022-03-15 | -$173.11M derived: sum of 3 quarters · filed 2022-03-15 | -$179.21M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$49.98M 10-Q · filed 2021-11-10 | -$57.38M derived: sum of 2 quarters · filed 2021-11-10 | -$63.47M 10-Q · filed 2021-11-10 | -$61.17M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$7.39M 10-Q · filed 2021-08-16 | -$13.49M 10-Q · filed 2021-08-16 | -$11.19M derived: sum of 3 quarters · filed 2021-08-16 | -$23.11M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$6.09M 10-Q · filed 2021-05-12 | -$3.80M derived: sum of 2 quarters · filed 2021-05-12 | -$15.72M derived: sum of 3 quarters · filed 2021-05-12 | -$26.24M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $2.30M 10-K · filed 2020-03-26 | -$9.63M derived: sum of 2 quarters · filed 2020-11-09 | -$20.14M derived: sum of 3 quarters · filed 2020-11-09 | -$31.83M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$11.92M 10-Q · filed 2020-11-09 | -$22.44M derived: sum of 2 quarters · filed 2020-11-09 | -$34.13M 10-Q · filed 2020-11-09 | -$42.74M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$10.52M 10-K · filed 2020-03-26 | -$22.21M 10-Q · filed 2019-08-12 | -$30.81M derived: sum of 3 quarters · filed 2020-03-26 | -$40.98M derived: sum of 4 quarters · filed 2020-03-26 |
| 2019-03-31 | -$11.69M 10-K · filed 2020-03-26 | -$20.30M derived: sum of 2 quarters · filed 2020-03-26 | -$30.46M derived: sum of 3 quarters · filed 2020-03-26 | -$39.49M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-12-31 | -$8.61M 10-K · filed 2020-03-26 | -$18.77M derived: sum of 2 quarters · filed 2020-03-26 | -$27.80M derived: sum of 3 quarters · filed 2020-03-26 | -$34.55M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$10.17M 10-K · filed 2020-03-26 | -$19.19M derived: sum of 2 quarters · filed 2020-03-26 | -$25.94M 10-Q · filed 2019-11-12 | -$32.65M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | -$9.02M 10-K · filed 2020-03-26 | -$15.77M 10-Q · filed 2019-08-12 | -$22.48M derived: sum of 3 quarters · filed 2020-03-26 | -$29.50M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | -$6.75M 10-K · filed 2020-03-26 | -$13.46M derived: sum of 2 quarters · filed 2020-03-26 | -$20.47M derived: sum of 3 quarters · filed 2020-03-26 | -$26.35M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | -$6.71M 10-K · filed 2019-03-28 | -$13.72M derived: sum of 2 quarters · filed 2019-03-28 | -$19.60M derived: sum of 3 quarters · filed 2019-03-28 | -$25.56M 10-K · filed 2019-03-28 |
| 2017-09-30 | -$7.02M 10-K · filed 2019-03-28 | -$12.90M derived: sum of 2 quarters · filed 2019-03-28 | -$18.85M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$5.88M 10-K · filed 2019-03-28 | -$11.84M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | -$5.96M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |